LPL and B-cell chronic lymphocytic leukemia: Likewise, the irreversible CD36 inhibitor SSO and the LPL inhibitor orlistat significantly reduced CLL cell O2 consumption and the effect of both inhibitors was significantly additive (Figure 3C).